Board of Managers

+ Expand all

Dean Maglaris is CEO and Chairman of the Board of Managers for Cytogel Pharma. Mr. Maglaris is a seasoned leader with more than 30 years in the pharmaceutical industry, joining Cytogel as its CEO in 2005. He has successfully guided the company through the identification of attractive compounds and the development of its lead compound, CYT-1010, which is entering Phase 2 clinical development, following a successful Phase 1 study in humans. Mr. Maglaris has long understood the need for a breakthrough solution to effectively and safely treat moderate to severe pain  and has recognized the potential benefits CYT-1010 could provide to patients. As such, Cytogel has a clear priority on developing this new class of drugs and continually pursuing new intellectual property, which has resulted in several issued patents.

Understanding the benefits that critical drug development can have on patients, Mr. Maglaris held leadership positions at Pfizer ranging from general management, product and business development and marketing.  His experience covers the spectrum of major therapeutic areas in pharmaceuticals as well as a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $2.0 billion each.  He attributes that success to constantly focusing on discovering and developing drug solutions that actually address the needs of the patients and their providers, in a meaningful and comparatively better way.

Mr. Maglaris has been active in the industry and has participated as a member of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He served as the Chair of the Board of Trustees of the University of Vermont, Chairman of the Board of Directors of the AmeriCares Foundation and an officer of the Board of Trustees of the New Canaan Country School in New Canaan, CT.  He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.

Steven G. Chrust is an outside manager on Cytogel's Board of Managers and is a member of the Compensation Committee.  He is founder and Senior Managing Partner of Centripetal Capital Partners, a private equity investment firm founded in 2004. He is also Founder and President of SGC Advisory Services, Inc., since 1991. Mr Chrust serves on several boards, including as Chairman of APJeT, Inc. and IMCS. He is a member of the Association for Investment Management and Research and the New York Society of Securities Analysts. He has lectured at the Harvard Business School and testified before Congress concerning the break-up of AT&T, and before state public utility commissions on various regulatory matters.

In 1994, he co-founded WinStar Communications, Inc., a facilities based local telecommunications provider utilizing fixed wireless technology and served as its Vice Chairman through 1998. Mr Chrust also served as Chairman of Worlds.com between 1999-2001.

Mr. Chrust began his career at Sanford C. Bernstein & Co., Inc., a financial institution handling more than $400 billion in client assets, now known as AllianceBernstein or AB. While at Bernstein, he was Director of Technology Research and ranked in the top tier of telecommunications analysts for more than a decade by Institutional Investor and ranked the #1 analyst in the sector for five consecutive years in their all-star ranking. Mr. Chrust is a graduate of Bernard M. Baruch College of the City University of New York and attended its business graduate school.

Alan W. Dunton, MD is a member of Cytogel’s Board of Managers and is also the Company's Chief Clinical Advisor.  He has devoted his career to the discovery and development of new prescription and OTC drug products. He is a creative and visionary leader who has successfully translated his scientific and clinical/medical knowledge into developing and achieving approval of over 20 commercially successful Rx and OTC drugs. He has led major pharma R&D and Regulatory divisions as well as has been CEO/COO both public and private biotechnology companies. Dr. Dunton has spearheaded organizational transformations in large and small companies. He has built a successful consulting company, Danerius, LLC, founded in 2006. He has also been appointed or elected Director of several Public/Private Companies serving in capacities as Non-Executive Board Chair, Member or Chair of the Compensation, Audit or Nominating/Governance Committees.

Prior to founding Danerius, Dr. Dunton served as CEO of Panacos Pharmaceuticals as well as Metaphore Pharmaceuticals – both biotechnology companies. He was also the President and Managing Director of the Janssen Research Foundation, the R&D and Regulatory arm of the pharmaceutical’s division at Johnson and Johnson. Previously, he was with Roche, Syntex and Novartis (as CIBA-GEIGY).

Dr. Dunton holds a MD from New York University School of Medicine, where he completed his residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. He is a diplomat of the American Board of Internal Medicine and currently licensed to practice medicine in New Jersey and New York. He received his Bachelor of Science degree in biochemistry, magna cum laude, from State University of NY at Buffalo. Dr. Dunton was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his research in medical ethics.

Cassandra Klimp is a founder and initial investor of Cytogel Pharma who has served as a non-executive director since 2006. She is a senior member of Meridian Partners LLC, a technology venture advisory firm,  with 30 years of experience in corporate banking, project management and entrepreneurship. Her career began in the field  for CL Peck Contractors in Los Angeles,  a design build firm  known for many of Los Angeles' storied  landmarks.  She segued into corporate lending for US Bank Corp, formerly First Bank Systems, where she financed commercial real estate development followed by years as a corporate lender to multibank holding companies in Minnesota, the Dakotas and Iowa in addition to working on divestiture of First Bank branches in the Dakotas.

Ms. Klimp has performed a range of advisory functions for profit and non-profit organizations with an emphasis on elder care and wellness issues.  She served on the board of directors of the Waveny Care Center, New Canaan, CT for eight years, co-chairing the design and construction of a state of the art Alzheimer wing which received national recognition.  Ms. Klimp is a native of Minnesota and a graduate of the University of Minnesota.

Joseph J. Rucci, Jr serves as an outside manager on the Company's Board of Managers and is also a member of the Compensation Committee. Mr. Rucci is founder/member of the Rucci Law Group with offices in Connecticut. He concentrates in the areas of business law, Trust and estates and not-for-profit organizations. He is admitted to practice before the Connecticut Bar, the United States District Court for Connecticut and the United States Court of Appeals for the First Circuit, as well as the United States Supreme Court.

Mr. Rucci is a director  of the AmeriCares Foundation, Inc. and serves on both the Governance and Audit /Risk committees; a member of Rotary International and of the Sovereign Order of Malta. Mr. Rucci has been recognized for his expertise by The Martindale Hubbell Bar Register of Preeminent Lawyers and the National Directory of Who's Who on Executives and Professionals. Mr. Rucci was awarded a Juris Doctorate from the Villanova University School of Law and graduated from Fairfield University.

Frederick W. Telling, PhD serves as an outside manager of Cytogel’s Board of Managers and is also a member of the Compensation Committee.  Dr. Telling brings industry insight after serving Pfizer for 30 years. Dr. Telling was elected a Corporate Vice President of Pfizer Inc and its Vice President of Corporate Strategic Planning and Policy in October 1994. He oversaw the company's realignment and focus on its human and animal health business, divesting its Food Science and Medical Technology groups, while acquiring Warner Lambert, Pharmacia and various consumer product brands. Concurrently, Dr. Telling was responsible for the company's policy development and he represented the company in many industry-related outside Boards, including BIO where he served on its Board for over 10 years.

Currently the Chairman of Oragenics in Tampa, Florida Dr. Telling is also a Director of Eisai N.A. Inc. in Woodcliff Lake, New Jersey. Dr. Telling chairs the Compensation Committee and serves on the Audit Committee of Oragenics.

He is a member of the Board of the United Hospital Fund and an emeritus member of the Boards of several organizations with which he remains involved, including the National March of Dimes Foundation, EAA, ORBIS, and the Smithsonian National Air & Space Museum. Dr. Telling is the President of the T-6 Racing Association and a member of The Metropolitan Club of Washington, DC.

Dr. Telling received his BA from Hamilton College and his Master's of Industrial and Labor Relations and PhD in Economics and Public Policy from Cornell University.